{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:04:55Z","timestamp":1789729495088,"version":"4.0.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD200 and its receptor CD200R form a myeloid-centered immune checkpoint that normally restrains myeloid activation and limits tissue damage, but many solid tumors co-opt this pathway to suppress antitumor immunity. CD200\u2013CD200R signaling is highly context-dependent, varying even among models of the same cancer type. In melanoma and breast carcinoma, it can either suppress protumor inflammation or promote tumor growth and metastasis depending on the model, whereas in neuroblastoma; glioblastoma and other central nervous system tumors; cutaneous and head and neck squamous cell carcinoma; colorectal cancer; and several endocrine, ovarian, and pancreatic cancers, it consistently suppresses macrophage, dendritic cell, natural killer cell, and CD8+ T-cell activation, impairs phagocytosis and antigen presentation, and drives immunosuppressive infiltration. Non-small cell lung cancer and renal cell carcinoma emerge as two additional, less-characterized but clinically important contexts warranting further investigation. CD200R1\u2013CD200 has also recently been identified as a macrophage phagocytosis checkpoint that functions independently of CD47\u2013SIRP\u03b1, placing it within the expanding family of innate immune checkpoints. Rather than treating CD200\u2013CD200R as a universally protumorigenic target, we propose a context-dependent framework\u2014incorporating tumor type, microenvironmental architecture, and dominant myeloid and lymphoid programs\u2014to guide tumor-specific therapeutic strategies in solid cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1950382","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:45:18Z","timestamp":1789728318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CD200\u2013CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Manas Ranjan","family":"Sahu","sequence":"first","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inemai","family":"Ezhil","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Akkanapally","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujit","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ohio State University","place":["Columbus, OH, United States"]},{"name":"Division of Medical Oncology, Department of Internal Medicine, Ohio State University","place":["Columbus, OH, United States"]},{"name":"Comprehensive Cancer Center, Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.191","article-title":"Regulation of myeloid cell function through the CD200 receptor","volume":"176","author":"Jenmalm","year":"2006","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00023-6","article-title":"Lymphoid\/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function","volume":"13","author":"Wright","year":"2000","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/s41467-025-60456-3","article-title":"CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPalpha-CD47 to suppress tumor growth","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5595","article-title":"CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy","volume":"178","author":"Kretz-Rommel","year":"2007","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106904","article-title":"CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor-associated myeloid cells","volume":"26","author":"Lin","year":"2023","journal-title":"iScience"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600052","article-title":"A critical role for CD200R signaling in limiting the growth and metastasis of CD200+ melanoma","volume":"197","author":"Liu","year":"2016","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.739816","article-title":"CD200 blockade modulates tumor immune microenvironment but fails to show efficacy in inhibiting tumor growth in a murine model of melanoma","volume":"9","author":"Talebian","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123326","article-title":"CD200\/CD200R: Bidirectional role in cancer progression and immunotherapy","volume":"11","author":"Nip","year":"2023","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.18632\/oncotarget.28354","article-title":"The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy","volume":"14","author":"Shao","year":"2023","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2767-9764.CRC-24-0568","article-title":"First-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid Malignancies","volume":"5","author":"Kummar","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.03.015","article-title":"Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha","volume":"46","author":"Chen","year":"2009","journal-title":"Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041602","article-title":"CD200:CD200R interactions and their importance in immunoregulation","volume":"22","author":"Kotwica-Mojzych","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152073","article-title":"Characterization of CD200 ectodomain shedding","volume":"11","author":"Wong","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3034","article-title":"Characterization of the CD200 receptor family in mice and humans and their interactions with CD200","volume":"171","author":"Wright","year":"2003","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901531","article-title":"Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells","volume":"183","author":"Mihrshahi","year":"2009","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.2.774","article-title":"Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells","volume":"162","author":"Gorczynski","year":"1999","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000152118.51622.F9","article-title":"Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R","volume":"79","author":"Gorczynski","year":"2005","journal-title":"Transplantation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.913094","article-title":"Role of CD200\/CD200R signaling pathway in regulation of CD4+T cell subsets during thermal ablation of hepatocellular carcinoma","volume":"25","author":"Huang","year":"2019","journal-title":"Med Sci Monit"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32163","article-title":"CD200 is induced by ERK and is a potential therapeutic target in melanoma","volume":"117","author":"Petermann","year":"2007","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1637","article-title":"A critical function for CD200 in lung immune homeostasis and the severity of influenza infection","volume":"9","author":"Snelgrove","year":"2008","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.12659\/msm.895245","article-title":"Over-expression of CD200 predicts poor prognosis in cutaneous squamous cell carcinoma","volume":"22","author":"Li","year":"2016","journal-title":"Med Sci Monit"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0046-9","article-title":"CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy","volume":"2","author":"Moertel","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1088038","article-title":"Cancel cancer: The immunotherapeutic potential of CD200\/CD200R blockade","volume":"13","author":"Choe","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.477","article-title":"CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor","volume":"31","author":"Rygiel","year":"2012","journal-title":"Oncogene"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.75","article-title":"Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150750","article-title":"CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis","volume":"132","author":"Morgan","year":"2022","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.002","article-title":"CD200R signaling in tumor tolerance and inflammation: A tricky balance","volume":"24","author":"Rygiel","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031442","article-title":"Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions","volume":"7","author":"Talebian","year":"2012","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040472","article-title":"Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy","volume":"40","author":"Wang","year":"2010","journal-title":"Eur J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.317","article-title":"Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response","volume":"34","author":"Erin","year":"2015","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2258-3","article-title":"Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6","volume":"136","author":"Podnos","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02589-6","article-title":"CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment","volume":"69","author":"Xin","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3251","article-title":"The CD200-CD200R axis promotes squamous cell carcinoma metastasis via regulation of cathepsin K","volume":"81","author":"Khan","year":"2021","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104723","article-title":"Targeting tumor-associated macrophages in head and neck squamous cell carcinoma","volume":"106","author":"Li","year":"2020","journal-title":"Oral Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4380","article-title":"The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma","volume":"70","author":"Stumpfova","year":"2010","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.09.001","article-title":"Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-beta-catenin-driven M2 macrophage","volume":"23","author":"Shin","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01556-0","article-title":"CD200R blockade enhances anti-tumor immunity by unleashing NK and CD8+ T cells in tumor","volume":"46","author":"Zhang","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad006","article-title":"Combination CD200R\/PD-1 blockade in a humanised mouse model","volume":"3","author":"Fellermeyer","year":"2023","journal-title":"Immunother Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000189","article-title":"CD200 promotes immunosuppression in the pancreatic tumor microenvironment","volume":"8","author":"Choueiry","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqx071","article-title":"CD200 expression in neuroendocrine neoplasms","volume":"148","author":"Love","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215501","article-title":"Multiplex quantitative analysis of tumor-infiltrating lymphocytes, cancer-associated fibroblasts, and CD200 in pancreatic cancer","volume":"13","author":"MacNeil","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0429-6","article-title":"Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200","volume":"57","author":"Siva","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081788","article-title":"Analysis of intra-tumoral macrophages and T cells in non-small cell lung cancer (NSCLC) indicates a role for immune checkpoint and CD200-CD200R interactions","volume":"13","author":"Tondell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051024","article-title":"Quantitative assessment of CD200 and CD200R expression in lung cancer","volume":"13","author":"Vathiotis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143294","article-title":"Primary and acquired resistance against immune check inhibitors in non-small cell lung cancer","volume":"14","author":"Sun","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-179","article-title":"ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression","volume":"8","author":"Fritzsche","year":"2008","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020316","article-title":"NK cell-based immunotherapy in renal cell carcinoma","volume":"12","author":"Terren","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/abt\/tbab002","article-title":"Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer","volume":"4","author":"Deng","year":"2021","journal-title":"Antib Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00262-024-03678-6","article-title":"CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival","volume":"73","author":"Wedig","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-020-00989-w","article-title":"Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity","volume":"13","author":"Kuo","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1950382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:45:19Z","timestamp":1789728319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1950382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1950382"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1950382","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1950382"}}